Eton Pharmaceuticals (NASDAQ:ETON) Insider Sells 25,000 Shares

Key Points

• Insider David Krempa sold 25,000 Eton Pharmaceuticals shares at an average price of $65.07, generating $1.63 million and reducing his direct ownership by 40.31% to 37,025 shares.
• Eton shares rose 1.5% to $64.43, near the company’s 52-week high, after quarterly results beat expectations: adjusted EPS was $0.43 versus a $0.19 consensus estimate, while revenue reached $37.59 million.
• Analyst sentiment remains mixed but constructive, with four Buy ratings and two Sell ratings; the consensus rating is Hold and the average price target is $67.50.

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) insider David Krempa sold 25,000 shares of the company's stock in a transaction on Monday, August 24th. The shares were sold at an average price of $65.07, for a total value of $1,626,750.00. Following the transaction, the insider directly owned 37,025 shares in the company, valued at $2,409,216.75. The trade was a 40.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

David Krempa also recently made the following trade(s):

• On Tuesday, May 26th, David Krempa sold 37,524 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $31.49, for a total value of $1,181,630.76.
• On Wednesday, May 27th, David Krempa sold 19,679 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $31.47, for a total value of $619,298.13.

Eton Pharmaceuticals Stock Up 1.5%

NASDAQ:ETON traded up $0.96 on Monday, hitting $64.43. 801,469 shares of the company's stock traded hands, compared to its average volume of 424,905. The company has a market cap of $1.84 billion, a PE ratio of 169.55 and a beta of 0.86. Eton Pharmaceuticals, Inc. has a 1 year low of $14.27 and a 1 year high of $66.37. The company has a current ratio of 1.52, a quick ratio of 1.30 and a debt-to-equity ratio of 0.41. The firm has a 50-day moving average price of $42.16 and a 200-day moving average price of $30.34.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.19 by $0.24. The business had revenue of $37.59 million during the quarter, compared to analysts' expectations of $27.11 million. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. Equities analysts anticipate that Eton Pharmaceuticals, Inc. will post 0.67 EPS for the current fiscal year.

Institutional Trading of Eton Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quarry LP bought a new position in Eton Pharmaceuticals during the third quarter worth about $37,000. Legal & General Group Plc acquired a new position in shares of Eton Pharmaceuticals in the 2nd quarter worth approximately $41,000. Toth Financial Advisory Corp bought a new position in shares of Eton Pharmaceuticals during the 2nd quarter worth approximately $43,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Eton Pharmaceuticals during the 4th quarter worth approximately $44,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Eton Pharmaceuticals in the 4th quarter valued at $74,000. Institutional investors own 27.86% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ETON shares. Canaccord Genuity Group raised their price objective on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a "buy" rating in a research note on Friday, August 14th. B. Riley Financial reissued a "buy" rating and issued a $70.00 price target (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. Craig Hallum boosted their price objective on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, July 28th. Wall Street Zen raised shares of Eton Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 13th. Finally, HC Wainwright lifted their target price on Eton Pharmaceuticals from $65.00 to $70.00 and gave the stock a "buy" rating in a research report on Friday, August 14th. Four equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $67.50.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source